Julie Leask | The Sydney Morning Herald
We’re sorry, this service is currently unavailable. Please try again later.
Dismiss
Julie Leask
Julie Leask is a professor at the Susan Wakil school of nursing and midwifery at the University of Sydney. She is an adviser to the World Health Organisation on improving vaccination uptake.
Opinion
It appears increasingly likely that the AstraZeneca vaccine may cause a new rare clotting condition. As experts work out how to treat and prevent it, Australia needs to accept its obligation to care for the few people who may be harmed in pursuit of the public good.
Julie Leask | WAtoday
Dismiss
Julie Leask
Julie Leask is a professor at the Susan Wakil school of nursing and midwifery at the University of Sydney. She is an adviser to the World Health Organisation on improving vaccination uptake.
Opinion
It appears increasingly likely that the AstraZeneca vaccine may cause a new rare clotting condition. As experts work out how to treat and prevent it, Australia needs to accept its obligation to care for the few people who may be harmed in pursuit of the public good.
7 hours ago
Latest
âWe were supposed to get, and contracted to get, 3.8 million AstraZeneca vaccines in these early weeks. Weâve got way less than that â 700,000,â he said.
âWe said many, many months ago, in fact about a month ago in particular, that we would hope to get in those early phases to around 80,000 a week. Now, we are getting up to those levels now as we conclude our third week.â
Advertisement
Opposition health spokesman Mark Butler said the governmentâs vaccination strategy was âfast becoming a complete messâ, with the country falling behind its goal of having all 678,000 people in phase 1a vaccinated within six weeks.
Will Australia get the Johnson & Johnson COVID-19 one-dose vaccine?
Posted
FriFriday 5
The Johnson & Johnson vaccine, similar to the AstraZeneca option, is a viral vector vaccine.
(
Share
Print text only
Cancel
Johnson & Johnson s COVID-19 vaccine has one big advantage over the two options currently on offer to Australia it doesn t need a booster shot.
Key points:
Scientists are examining if the jab will have a higher efficacy rate after two doses
Johnson & Johnson has submitted an application to the TGA for the provisional registration
The US Food and Drug Administration authorised the Johnson & Johnson jab for emergency use on February 27, making it the United States third regulator-approved coronavirus vaccine.
How Do We Know The COVID Vaccine Won t Have Long-Term Side-Effects? econintersect.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from econintersect.com Daily Mail and Mail on Sunday newspapers.